Introduction {#S0001}
============

Trigger finger disorder, also known as stenosing tenovaginitis, is a sudden release or locking of a finger during flexion or extension,[@CIT0001],[@CIT0002] which is due to hypertrophy at the intersection of the tendon with the tendon pulley and prevents normal forward and backward gliding of the tendon under the pulley. It is postulated that this disorder is caused by high pressure at the proximal edge of the A1 pulley and the discrepancy between the diameter of the flexor tendon and its sheath at the metacarpal head.[@CIT0002] The link between this disorder and repeated trauma is frequently highlighted in scholarly articles;[@CIT0002] however, the main etiology is still unclear.[@CIT0001]

Thumb (33% in adults and 90% in children) followed by ring finger (27%) are the most commonly involved fingers.[@CIT0002],[@CIT0003] Moreover, the right hand is more frequently involved compared to the left hand[@CIT0004],[@CIT0005] and the dominant hand is more frequently involved compared to the non-dominant hand.[@CIT0003] The age distribution of trigger finger is showing a pattern that includes children under the age of 6 years and adults over 40 years old, especially women aged between 50 and 60 years old.[@CIT0004] The prevalence of trigger finger is higher in patients with rheumatoid arthritis[@CIT0002] and diabetes (with a prevalence of 10% to 20%)[@CIT0006],[@CIT0007] compared to the normal population (with a prevalence of 2% to 3%).[@CIT0007] Additionally, patients with rheumatoid arthritis and diabetes can experience trigger finger in multiple fingers.[@CIT0002],[@CIT0007] Other conditions associated with the disease include carpal tunnel syndrome, osteoarthritis, de quervain's tenosynovitis, and hypothyroidism.[@CIT0008]--[@CIT0011]

Diagnosis is completely based on history and clinical examination, and no paraclinical examination is required without a history of trauma or inflammatory arthritis.[@CIT0002],[@CIT0012] In history taking, the patient is typically complainant about pain in the PIP joint, morning stiffness, and tenderness on the A1 pulley; however, the main pathology is in the MCP joint. In more severe cases, the patient may have a history of a locking finger that could be resolved either passively or actively.[@CIT0001],[@CIT0002] The pain and locking of the finger caused by the disease will result in functional limitation.[@CIT0002]

Treatments for this disease are diverse and include NSAIDs, cryotherapy, hand splints, corticosteroid injections, percutaneous or open surgery,[@CIT0001] and musculoskeletal ultrasound.[@CIT0013],[@CIT0014] Selected treatment for each patient depends on the severity of triggering (the more severe cases respond better to injection), the onset of triggering, previous treatment, the patient's level of activity, and the patient's and therapist's preferences.[@CIT0001],[@CIT0002] The proposed splint holds the MCP joint at 0° of extension[@CIT0001] or 10° to 15° of flexion for up to 3 to 6 weeks.[@CIT0002] The splint was not effective in patients with multiple finger involvement. The relapse rate with this treatment was 12% over a year.[@CIT0015] Corticosteroid injection was less effective in patients with multiple finger involvement, such as diabetic and rheumatoid patients, and in those with symptoms lasting longer than 4 months.[@CIT0002],[@CIT0016] Tendon rupture is more likely in patients with rheumatoid arthritis after corticosteroid injection and repeated injections are not recommended.[@CIT0002] For other patients, the maximum number of injections is up to three injections according to the new European guidelines.[@CIT0001] Surgery is indicated in the case of injection failure. Patients with diabetes, rheumatoid arthritis, multiple finger involvement, and lower ages will require surgery at the start of treatment. Complications of this type of treatment are infection, nerve injury, and bowing of flexor tendons.[@CIT0002] Musculoskeletal ultrasound has also gained an important place in the diagnosis of and intervention for musculoskeletal disorders, including trigger finger, due to being inexpensive, non-invasive, repeatable, convenient, not requiring any exposure to radiation, and providing dynamic imaging.[@CIT0013],[@CIT0014]

The extracorporeal shock waves are defined as sound waves that can maximize the pressure of the target tissue over a few nanoseconds.[@CIT0017] Recently, extracorporeal shock wave therapy (ESWT) has been proposed as an alternative treatment in patients not responding to conservative treatments. This method has been used in orthopedic diseases such as plantar fasciitis, lateral epicondylitis, calcific shoulder tendonitis, non-union of long bones,[@CIT0017]--[@CIT0022] patellar tendinopathy, femoral head avascular necrosis, and carpal tunnel syndrome. The success rate of this method varies between 65% and 91% in the treatment of these diseases in various studies, while the complications are low and can be neglected.

The shock wave has two focus and radial types, which do not have a focal point in the radial type and can be used without specifying painful points. The use of this method has been approved by the FDA for plantar fasciitis and lateral epicondylitis.[@CIT0017] The contraindications of this method include hemorrhagic diseases and pregnancies. Its complications in low to moderate energies include femoral head osteonecrosis.[@CIT0017] Other complications such as tendon rupture have also been reported.[@CIT0023] Lin et al reported a tendon rupture in calcific Achilles tendonitis secondary to surgery for Hoagland disease. Additionally, they also noted some other risk factors for tendon rupture such as previous surgery in the area, long-term usage of NSAIDs, and corticosteroid injection in the area[@CIT0023] which should be considered when using ESWT.

In the literature review, there was only one study comparing the effect rate of corticosteroid injection and ESWT. There was no statistically significant difference in the effect rate between the two methods after 1, 3, and 6 months of follow up.[@CIT0024] Regarding the complications and disadvantages mentioned for the methods used in the treatment of trigger finger disorder, this study investigated the effect of extracorporeal shock wave therapy in the treatment of amateur sporting participants with trigger finger.

Methods {#S0002}
=======

This study was an interventional study, with a registration number of IRCT20170915036191N2, recruiting 19 patients with trigger finger disorder referred to Physical Medicine and Rehabilitation Clinics of Isfahan University of Medical Sciences. Importantly, this trial was approved by the research ethics committee of Isfahan University of Medical Sciences, and it was conducted in accordance with the Declaration of Helsinki. After explaining the benefits, goals, and potential risks of treatment, patients were enrolled in the study and signed the informed written consent. The diagnosis was based on the accepted definition of trigger finger disorder according to European guideline ICD10.[@CIT0001] Importantly, amateur sporting participants in the past 2 years were recruited.

Inclusion criteria include: a) ages over 18 years old; b) trigger finger of grade one or more; c) receiving previous treatment more than 6 months ago; and d) lack of hemorrhagic diseases, pregnancies, malignancies, localized infections, heart arrhythmia, and pacemaker.

Evaluation of pain severity, severity of triggering, and functional impact of triggering was carried out using the Visual Analogue Scale, Trigger Finger Score suggested by Quinnell,[@CIT0025] and Quick-Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire,[@CIT0026] respectively, before intervention, immediately after intervention, and in 6 and 18 weeks after intervention.

Trigger Finger Score suggested by Quinnell: at the zero score, the finger is not locked, but it has crepitation during movement. A one score is given when the finger is not locked, but it has sudden movements. At the two score, the finger locking could be modified actively. A three score is given when the finger locking could be modified passively. At the four score, the finger locking is not modifiable.[@CIT0025]

Quick-Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire: in comparison to the original 30-item DASH questionnaire, the Quick-DASH is a self-report questionnaire containing 11 items. It measures the ability of individuals to perform certain upper extremity activities to complete tasks, absorb forces, and it also measures the severity of symptoms. The Quick-DASH uses a 5-point Likert scale from which the patients select an appropriate number corresponding to their severity level or function level.[@CIT0026] Considering that the reliability, validity, and cross-cultural adaptation of the Quick DASH and DASH Questionnaire have been done in Persian, the Persian Quick Dash Questionnaire was used.[@CIT0027],[@CIT0028]

Each patient was treated with ESWT in three sessions with a 1-week interval. The treatment protocol for each session was using radial shock wave therapy with 1000 shocks, at an energy flux density of 2.1 bar and a frequency of 15 Hz.[@CIT0024] Moreover, the treatment protocol for using focused shock wave therapy was 500 shocks, at an energy flux density of 0.1 bar and a frequency of 4 Hz. Focused shock wave therapy was used directly on the nodule and the maximum tenderness site while the radial shock wave therapy was used on the peripheral tissues of the nodule. The DUOLITH SD1 Tower, Switzerland was used for intervention.

Data were analyzed using Statistical Package for the Social Sciences (SPSS) software version 17.0. Demographic data were analyzed using descriptive statistics. ANOVA was utilized to analyze changes in pain severity, severity of triggering, and functional impact of triggering during follow-ups. The level of significance was set at 0.01 (*P*\<0.01).

Results {#S0003}
=======

Nineteen patients participated in this study, of which 27.8% had carpal tunnel syndrome, 11.1% had diabetes, and 16.7% had hypothyroidism. 27.8% of patients had trigger finger in their middle finger and 50% had this problem in their thumb. 66.7% of the participants had not received any treatment for their trigger finger. [Table 1](#T0001){ref-type="table"} shows the demographic information of the participants.Table 1Demographic Information of the Participants in This StudyGenderInjured HandTriggering FingerPrevious Medical HistoryPrevious Treatment HistoryMenWomenLeftRightThumbMiddleRingCarpal Tunnel SyndromeDiabetesDiabetes and Carpal Tunnel SyndromeHypothyroidismDiabetes and Rheumatoid ArthritisNo HistoryCorticosteroid InjectionMassageSplintsNo TreatmentNumber (n)61212695452331421312

As [Table 2](#T0002){ref-type="table"} depicts, there were statistically significant differences with regard to reduction of the pain severity, severity of triggering, and functional impact of triggering before intervention, immediately after intervention, and in 6 and 18 weeks after intervention (*P*\<0.01).Table 2The Effect of Extracorporeal Shock Wave Therapy on Reducing the Pain Severity, Severity of Triggering, and Functional Impact of Triggering Before Intervention, Immediately After Intervention, and in 6 and 18 Weeks After InterventionVariableMean±Standard DeviationF-value*P*-valueSeverity of TriggeringBefore Intervention3.50±0.9617.480.001\*Immediately after Intervention3.25±1.066 Weeks after Intervention2.44±1.3118 Weeks after Intervention1.75±1.95Pain SeverityBefore Intervention6.13±2.2750.580.001\*Immediately after Intervention3.31±1.776 Weeks after Intervention0.94±1.1218 Weeks after Intervention0.56±1.21Functional Impact of TriggeringBefore Intervention373.44±143.3123.570.001\*Immediately after Intervention332.81±138.966 Weeks after Intervention215.63±153.5318 Weeks after Intervention167.19±181.36[^1]

The effect of ESWT on reducing severity of triggering immediately after intervention did not yield a statistically significant difference compared to before intervention (*P*\>0.01). Moreover, the effect of ESWT on reducing pain severity, severity of triggering, and functional impact of triggering in the 6 weeks after intervention did not yield a statistically significant difference compared to the 18 weeks after intervention (*P*\>0.01) ([Table 3](#T0003){ref-type="table"}).Table 3Comparing the Effect of Extracorporeal Shock Wave Therapy on Reducing the Pain Severity, Severity of Triggering, and Functional Impact of Triggering (1=Before Intervention, 2=Immediately After Intervention, 3=6 Weeks After Intervention and 4=18 Weeks After Intervention)Severity of TriggeringPain SeverityFunctional Impact of TriggeringFollow-up1 & 21 & 31 & 42 & 32 & 43 & 41 & 21 & 31 & 42 & 32 & 43 & 41 & 21 & 31 & 42 & 32 & 43 & 4*P*-value0.620.001\*0.003\*0.001\*0.006\*0.140.001\*0.001\*0.001\*0.001\*0.001\*10.001\*0.002\*0.001\*0.006\*0.001\*0.085[^2]

Moreover, the F-value obtained from Pillai's Trace was 0.735 for changes in severity of triggering, 0.851 for changes in pain severity, and 0.751 for changes in functional impact of triggering during the intervention period (*P*\<0.01).

Discussion {#S0004}
==========

Trigger finger disorder is a sudden release or locking of a finger during flexion or extension. Treatments for this disease are diverse and include NSAIDs, hand splints, corticosteroid injections, and percutaneous or open surgery. Regarding the complications and disadvantages mentioned for the methods used in the treatment of trigger finger disorder, the aim of this study was to investigate the effect of ESWT in the treatment of patients with trigger finger.

According to [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}, regarding the effect of ESWT on severity of triggering of patients with trigger finger before intervention, immediately after intervention, and in 6 and 18 weeks after intervention, it can be concluded that the mean value of severity of triggering has descended from 3.50 before the intervention to 1.75 in the 18 weeks after the intervention. However, this severity of triggering was not significantly observed immediately after the intervention, and the peak effect of ESWT on reducing severity of triggering was in the 6 weeks after the intervention continuing to 18 weeks after the intervention.

Regarding the effect of ESWT on the functional impact of triggering before intervention, immediately after intervention, and in 6 and 18 weeks after intervention, it can be concluded that the mean value of the functional impact of triggering has descended from 373.44 before the intervention to 167.19 in the 18 weeks after the intervention. [Table 3](#T0003){ref-type="table"} demonstrates the rapid impact of ESWT on increasing the functional status of patients with trigger finger, as the 40.36 decrease in the functional impact of triggering score immediately after intervention was statistically significant and this reduction continues through the 18 weeks after intervention. Similarly, the pain severity descended from 6.13 before intervention to 0.56 in the 18 weeks after intervention. Moreover, the reduction in pain severity, by making a difference value of 2.82 in comparing before and immediately after the intervention, yielded a statistically significant difference. In a similar study by Malliaropoulos et al, the use of radial ESWT led to a pain severity reduction of 7.1 on the Visual Analogue Scale in comparing the baseline and the 1 year after intervention follow up.[@CIT0029] In Malliaropoulos et al's study, the mean value of pain severity was 7.8 at baseline, which is much higher than the mean value reported by the participants in our study. Considering the F-value obtained from Pillai's Trace, it can be stated that 73.5% of changes in severity of triggering, 85.1% of changes in pain severity, and 75.1% of changes in functional impact of triggering during the intervention period were due to ESWT.

In the only randomized controlled study conducted in this area, Yildirim et al compared the effects of ESWT and corticosteroid injection on reducing pain severity, severity of triggering, and functional impact of triggering. In this study, 40 patients with trigger finger were allocated into two groups of ESWT and corticosteroid injection.[@CIT0024] In similar findings to the results of our study, the ESWT group achieved a reduction of 4.9 in pain severity in comparing the baseline and 18 weeks after the intervention. Additionally, a significant reduction in severity of triggering and functional impact of triggering was also reported.[@CIT0024]

Currently, ESWT is widely used in the treatment of tendinopathies. It is believed that ESWT acts by stimulating biological activity in cells leading to the creation of mechanosensitive biofeedback between the sound waves and these cells. Studies have shown that an increase in the angiotensin factor by ESWT results in neovascularization and appropriate vascular support of the injured tendon leading to its repair. Moreover, ESWT stimulates the synthesis of nitric oxide which will suppress the progression of inflammation.[@CIT0030]--[@CIT0033] However, the effectiveness of ESWT depends on several factors including the location of applying pressure, the energy flux density, the overall energy, adherence to the principles of shockwave production, and the device itself.[@CIT0034] Moreover, the application of concomitant local anesthesia is demonstrated to reduce the effectiveness of ESWT;[@CIT0035],[@CIT0036] therefore, the ultrasound gel was the only conductive gel used in this study. It should be also noted that the protocol used by Yildirim et al was used in this study. Two of the limitations of this study were the lack of randomization in selecting the sample population and the lack of a control group. Moreover, the number of selected samples was relatively small. It is suggested that these constraints be considered in future studies.

It seems that ESWT leads to a reduction in pain severity, severity of triggering, and functional impact of triggering. This reduction persisted until the 18th week after the intervention. It is recommended to use extracorporeal shock wave therapy in terms of a non-invasive intervention with no significant complications for patients with trigger finger.
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